Loading...
•
Mar 31, 2021
Ardelyx Q1 2021 Earnings Report
Reported first quarter financial results and business highlights.
Key Takeaways
Ardelyx reported first quarter revenue of $6.6 million, primarily from a milestone payment. Research and development expenses increased to $20.5 million, and general and administrative expenses rose to $17.1 million. The net loss for the quarter was $33.2 million.
PDUFA date for tenapanor extended to July 29, 2021.
Received a $5 million milestone payment from Kyowa Kirin Co., Ltd.
Appointed Muna Bhanji, R.Ph., to the company’s board of directors.
Presented posters at the National Kidney Foundation 2021 Spring Clinical Meeting and the ISN World Congress of Nephrology 2021.
Revenue by Segment
Forward Guidance
The company is preparing for the potential approval and launch of tenapanor following the PDUFA date extension to July and remains confident in the data included in their New Drug Application.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...